{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.74","value":"95.15"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG001","spread":"NA","value":"69.34"},{"groupId":"OG002","spread":"2.24","value":"63.98"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG003","spread":"NA","value":"62.58"},{"groupId":"OG004","spread":"7.86","value":"63.65"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG005","spread":"NA","value":"78.90"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG006","spread":"NA","value":"57.74"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG007","spread":"NA","value":"68.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"3.86","value":"69.65"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG003","spread":"NA","value":"60.71"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG004","spread":"NA","value":"70.20"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG005","spread":"NA","value":"78.94"},{"comment":"Only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.","groupId":"OG007","spread":"NA","value":"63.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"description":"PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.","id":"OG000","title":"Dose Escalation Part: 0.3 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.","id":"OG001","title":"Dose Escalation Part: 0.6 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.","id":"OG002","title":"Dose Escalation Part: 0.9 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.","id":"OG003","title":"Dose Escalation Part: 1.2 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.","id":"OG004","title":"Dose Escalation Part: 1.5 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.","id":"OG005","title":"Dose Escalation Part: 1.8 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG006","title":"Dose Escalation Part: 2.0 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.","id":"OG007","title":"Dose Escalation Part: 2.2 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.","reportingStatus":"POSTED","timeFrame":"Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)","title":"Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE","type":"SECONDARY","unitOfMeasure":"hours"}